Stay updated with breaking news from Adrian Woolfson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myelomaPhase 1/2 ...
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.